Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing l-Thyroxine plus Liothyronine with l-Thyroxine Alone
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Substituting part of the dose of l-thyroxine with small but supraphysiologic doses of liothyronine in hypothyroid patients has yielded conflicting results. OBJECTIVE: To evaluate combinations of L-thyroxine plus liothyronine in hypothyroid patients that match the proportions present in normal secretions of the human thyroid gland. DESIGN: Randomized, double-blind, crossover trial. SETTING: Academic research hospital. PARTICIPANTS: 28 women with overt primary hypothyroidism. INTERVENTION: Crossover trial comparing treatment with l-thyroxine, 100 microg/d (standard treatment), versus treatment with L-thyroxine, 75 microg/d, plus liothyronine, 5 microg/d (combination treatment), for 8-week periods. All patients also received L-thyroxine, 87.5 microg/d, plus liothyronine, 7.5 microg/d (add-on combination treatment), for a final 8-week add-on period. MEASUREMENTS: Primary outcomes included serum thyroid hormone levels, results of quality-of-life and psychometric tests, and patients' preference. Multiple biological thyroid hormone end points were studied as secondary outcomes. RESULTS: Compared with standard treatment, combination treatment led to lower free thyroxine levels (decrease, 3.9 pmol/L [95% CI, 2.5 to 5.3 pmol/L]), slightly higher serum levels of thyroid-stimulating hormone (increase, 0.62 mU/L [CI, 0.01 to 1.23 mU/L]), and unchanged free triiodothyronine levels. No improvement was observed in the other primary and secondary end points after combination treatment, with the exception of the Digit Span Test, in which the mean backward score and the mean total score increased slightly (0.6 digit [CI, 0.1 to 1.0 digit] and 0.8 digit [CI, 0.2 to 1.4 digits], respectively). The add-on combination treatment resulted in overreplacement. Levels of thyroid-stimulating hormone decreased by 0.85 mU/L (CI, 0.27 to 1.43 mU/L) and serum free triiodothyronine levels increased by 0.8 pmol/L (CI, 0.1 to 1.5 pmol/L) compared with standard treatment; 10 patients had levels of thyroid-stimulating hormone that were below the normal range. Twelve patients preferred combination treatment, 6 patients preferred the add-on combination treatment, 2 patients preferred standard treatment, and 6 patients had no preference (P = 0.015). LIMITATIONS: Treatment with L-thyroxine, 87.5 microg/d, plus liothyronine, 7.5 microg/d, was an add-on regimen and was not randomized. CONCLUSIONS: Physiologic combinations of L-thyroxine plus liothyronine do not offer any objective advantage over l-thyroxine alone, yet patients prefer combination treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the available crossover trials, when examining the patients who completed the trials, four trials that incorporated 128 patients showed there was a preference for combination therapy (23,46,50,51)”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [50]
In the citing paper
“one trial of 26 participants showed benefit on a minority of measures (49)”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [49]
In the citing paper
“Some trials have excluded specific patient groups, such as those with mental illness, affective disorders, or untreated depression (48,49,52).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [49]
In the citing paper
“A crossover design is appealing because of the increase in statistical power due to the ability to perform paired analyses, as has been performed in prior studies (23,46,50,52,58,59,75,76,107).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [50]
In the citing paper
“Eleven trials were 5–16 weeks (23,46,49,51–53,58–60,71,79), three trials were 4–6 months (17,48,78), and one trial was 1 year in duration (47).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [49]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
WAIS-R manual : Wechsler adult intelligence scale-revised
Wechsler, D. (1981) · Medical Entomology and Zoology · Cited by 1,559
The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS?
Garratt, A. M., Ruta, D. A., Abdalla, M. I., Buckingham, J. K., & Russell, I. T. (1993) · BMJ · doi:10.1136/bmj.306.6890.1440 · Cited by 1,141
Translating Health Status Questionnaires and Evaluating Their Quality
Bullinger, M., Alonso, J., Apolone, G., Leplège, A., Sullivan, M., Wood-Dauphinee, S., Gandek, B., Wagner, A., Aaronson, N., Bech, P., et al. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00082-1 · Cited by 912
[Population reference values of the Spanish version of the Health Questionnaire SF-36].
Alonso, J., Regidor, E., Barrio, G., Prieto, L., Rodríguez, C., & de la Fuente, L. (1998) · PubMed · Cited by 552
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 1×
“As previous studies showed, for hypothyroid patients receiving L-thyroxine alone (34), awareness of disease may be responsible for this difference (35, 36).”
ResultBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 3×
“Of the 6 studies to date that have evaluated L-thyroxine–liothyronine treatment for hypothyroidism (Table 4), only the study by Bunevicius and colleagues (7, 8) found advantages of combined treatment over treatment with Lthyroxine alone.”
BackgroundMethodAdvances in Our Understanding of Thyroid Hormone Action at the Cellular Level*
OPPENHEIMER, J. H., SCHWARTZ, H. L., MARIASH, C. N., KINLAW, W. B., WONG, N. C. W., & FREAKE, H. C. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-3-288 · Cited by 476 · cited 1×
“However, triiodothyronine is the most active thyroid hormone because its affinity for the nuclear thyroid hormone receptor is 10- to 20-fold that of thyroxine (2, 3).”
BackgroundFish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353 · cited 1×
“The finding that patients presented with higher serum levels of free thyroxine when receiving standard treatment than euthyroid controls who had similar TSH values is in conceptual agreement with previous results in hypothyroid humans (37) and thyroidectomized rats (4).”
ResultZulewski, H., Müller, B., Exer, P., Miserez, A. R., & Staub, J.-J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3810 · Cited by 338 · cited 1×
“Immediately after blood sampling, participants had a small breakfast and an independent evaluator performed a battery of cognitive, affective, and quality-of-life tests, including the Zulewski score (16), POMS (17), Nottingham Health Profile and Short Form-36 Health Survey (18–22), Digit Symbol Substitution Test (23,…”
MethodMental state assessment of young and elderly adults in behavioral neurology
Weintraub, S. A. (1985) · Medical Entomology and Zoology · Cited by 336
Research works printed but not linked: 5
- Pilo A, 1990, Am J Physiol, 258, 715
- Zulewski H, 1997, J Clin Endocrinol Metab, 82, 771
- Alonso J, 1998, Med Clin (Barc), 111, 410
- Celesia GG, 1999, Electroencephalogr Clin Neurophysiol Suppl, 52, 53
- Pratt H, 1999, Electroencephalogr Clin Neurophysiol Suppl, 52, 69
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Among the five blinded, cross-over design trials comparing treatment preference (385,387,517,519,521), combination LT4/LT3 treatment was preferred to LT4 in four trials (387,517,519,521), whereas there was no significant difference in treatment preference in only one trial (385).”
InfluentialChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Chaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
“…replacement with a combination of T4 and T3, in comparison with T4 monotherapy, improves mental functioning in some but not all hypothyroid patients (Bunevicius et al., 1999; Nygaard et al., 2009), and most of the patients subjectively prefer combined treatment (Escobar-Morreale et al., 2005).”
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Metadata
- Authors
- Escobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J.
- Affiliations
- Hospital Universitario Ramón y Cajal (ES)
- From Hospital Ramón y Cajal, Madrid, Spain.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2005-03-15
- Volume
- 142
- Issue
- 6
- Pages
- 412-424
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2027530011
- Cited by
- 182
- References
- 35
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 9 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 7 · 2019: 8 · 2018: 12 · 2017: 8 · 2016: 11 · 2015: 6 · 2014: 8 · 2013: 5 · 2012: 11
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- primary hypothyroidism, liothyronine, levothyroxine, thyroid hormone replacement, free thyroxine, thyroid-stimulating hormone, free triiodothyronine, cognitive function, quality of life, patient preferences, overtreatment, women, crossover trial, dose titration, digit span
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypothyroidism, Middle Aged, Thyrotropin, Thyroxine, Triiodothyronine, Treatment Outcome, Patient Satisfaction, Cross-Over Studies, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing l-Thyroxine plus Liothyronine with l-Thyroxine Alone. https://app.cochat.ai/papers/10.7326/0003-4819-142-6-200503150-00007
- The paper
- Escobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005). Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing l-Thyroxine plus Liothyronine with l-Thyroxine Alone. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-142-6-200503150-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.